Chime Biologics, Kings Pharm Partner to Accelerate Biosimilar Launch

Chime Biologics, a contract development and manufacturing organization (CDMO), is joining forces with Kings Pharm to provide cell line development, early process development, global clinical and commercial manufacturing, and registration services to Kings Pharm. Chime Biologics will be the exclusive service provider to help Kings Pharm bring its asset to global markets.

Chime Biologics is launching global services for biosimilars to support clients biosimilar IND-filing, clinical sampling, commercial manufacturing, and regulatory service.

Jaehee Lee, advisor of Kings Pharm, said, “Kings Pharm is committed to developing new drugs for oncology and metabolic diseases for aging. We believe that life must be respected and that human life goes on. This anti-tumor biosimilar is the first collaboration project between Kings Pharm and Chime Biologics, and we are very pleased to enter into a strategic partnership with Chime for such an important project. We are willing to authorize the exclusive cooperation with Chime Biologics and look forward to further expanding the cooperation in the future for the benefit of patients.”

Jimmy Wei, president of Chime Biologics, said, “We are pleased to establish a strong partnership with Kings Pharm to accelerate the development and commercialization of this anti-tumor biosimilar. The biosimilar program is Chime Bio’s strength, our team has successful experience in developing several biosimilars and has a proprietary platform for high-expression cell line development, which allows us to provide low-cost biosimilar development services to clients all over the world. This collaboration is the beginning of our one-stop solution for biosimilars, we are proud to make every effort to support Kings Pharm to promote its biosimilars to market and increase the accessibility of biologics to patients globally.”